Filament Health To Discuss Its Drug Development Platform in Fireside Chat With Water Tower Research on April 4, 2024 at 12PM ET | Psychedelic Invest

VANCOUVER, BC, March 19, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, announced that since March 1, 2024 it has shipped its botanical psilocybin drug candidate, PEX010, to four countries for clinical trials at leading research institutions. PEX010 will be studied in Canada, the United States, Belgium, and Israel, for…

WuXi Biologics seeks spinout, HK listing of bioconjugates-focused joint venture

Another member of the WuXi AppTec family is set to be spun off and separately listed on the Hong Kong Stock Exchange, allowing the contract

July 11, 2023

Pfizer settles Biohaven kickback claims case for $59.7m – Pharmaceutical Technology

Pfizer acquired Biohaven for $11.6bn in October 2022 based on a strong sales forecast for Nurtec ODT. Image credit: Shutterstock/Molly Woodward. Pfizer has agreed to

January 27, 2025

Differing definitions of iron deficiency lead to divergent estimates of prevalence, study finds

How different ways of defining iron deficiency (ID) impact the prevalence estimates of this common disorder among women.

June 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.